Pharmacological senolysis reduces doxorubicin-induced cardiotoxicity and improves cardiac function in mice
Many anticancer agents used in clinics induce premature senescence in healthy tissues generating accelerated aging processes and adverse side-effects in patients. Cardiotoxicity is a well-known limiting factor of anticancer treatment with doxorubicin (DOX), a very effective anthracycline widely used...
Saved in:
Main Authors: | Araceli Lérida-Viso (Author), Alejandra Estepa- Fernández (Author), Ángela Morellá-Aucejo (Author), Beatriz Lozano-Torres (Author), María Alfonso (Author), Juan F. Blandez (Author), Viviana Bisbal (Author), Pilar Sepúlveda (Author), Alba García-Fernández (Author), Mar Orzáez (Author), Ramón Martínez-Máñez (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The roles and mechanisms of senescence-associated secretory phenotype (SASP): can it be controlled by senolysis?
by: Naoko Ohtani
Published: (2022) -
Fluorouracil and doxorubicin - cardiotoxic cytostatics in the workplace
by: Małgorzata Kupczewska-Dobecka, et al.
Published: (2020) -
Cardiotoxicity of doxorubicin - causes, prevention, prospects
by: Paweł Wesołowski, et al.
Published: (2022) -
Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
by: Irwin K. Cheah, et al.
Published: (2023) -
Bibliometric and visual analysis of doxorubicin-induced cardiotoxicity
by: Xiaoxiao Lin, et al.
Published: (2023)